RTI Surgical (RTI) is a global, industry leading surgical implant supplier that provides design, new product development, processing and manufacturing services in support of patients and leading medical technology companies. With expertise spanning tissue, biologics and hardware, we serve OEM partners across a diverse set of market segments, including but not limited to, Dental, Plastic and Reconstructive Surgery, Sports Medicine, Spine, Trauma and Urology/Urogynecology.
Location: United States,
Employees: 501-1000
Founded date: 1998
Mentions in press and media 7
| Date | Title | Description |
| 27.12.2021 | Surgalign : 2021 Women in Science Wednesday Honorees | 2021 Women in Science Wednesday Honorees December 27, 2021 At RTI Surgical, we are committed to gender equality and were delighted to recognize some of the outstanding women who use science to help patients by developing innovative solution... |
| 18.10.2013 | Medtronic signs deals with Lombard Medical, RTI Surgical | Medical device giant Medtronic (NYSE:MDT) notched a couple new agreements, signing away a patent dispute and extending an active partnership. Medtronic granted Lombard Medical Technologies (LON:LMT) a non-exclusive licenses to the "Jer... |
| 13.09.2010 | Athersys licenses stem cell technology in deal worth up to $40M | The deal could be worth up to $40.5 million to Athersys. The terms of the agreement call for Athersys to receive a $3 million license fee and up to $37.5 million in payments that are contingent upon RTI hitting unspecified development and r... |
| 13.09.2010 | Athersys inks $40 million licensing deal with orthopedic implant maker | Athersys Inc. (NSDQ:ATHX) licensed its stem cell technology to a Florida firm that makes orthopedic implants in a deal that could be worth more than $40 million. Alachua, Fla.-based RTI Biologics Inc. (NSDQ:RTIX) plans to develop and commer... |
| 09.02.2010 | RTI Biologics swings to Q4 black | RTI Biologics Inc. (NSDQ:RTIX) posted fourth-quarter sales of $42 million for the three months ended Dec. 31, 2009, up 12 percent compared with $37.4 million during the same period in 2008. Net income was $1.5 million, compared with a net l... |
| - | A&E Medical Corporation, A portfolio company of Vance Street Capital, acquires RTI Surgical’s Cardiothoracic closure business Follow us on LinkedIn | Acquisition further enhances A&E Medical’s sternal closure product portfolio and expands A&E’s penetration of the North American markets |
| - | Athersys licenses stem cell technology in deal worth up to $40M | Athersys Inc. (NASDAQ: ATHX) has licensed its stem cell technology to a Florida firm that makes orthopedic implants in a deal that could be worth more than $40 million. RTI Biologics Inc. plans to develop and commercialize implants based on... |